526 related articles for article (PubMed ID: 14701775)
1. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
Edelman MJ; Chansky K; Gaspar LE; Leigh B; Weiss GR; Taylor SA; Crowley J; Livingston R; Gandara DR
J Clin Oncol; 2004 Jan; 22(1):127-32. PubMed ID: 14701775
[TBL] [Abstract][Full Text] [Related]
2. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
4. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma.
Kakolyris S; Agelidou A; Androulakis N; Tsaroucha E; Kouroussis Ch; Agelidou M; Karvounis N; Veslemes M; Christophylakis Ch; Argyraki A; Geroyianni A; Georgoulias V
Lung Cancer; 2006 Jul; 53(1):59-65. PubMed ID: 16716447
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
Le QT; McCoy J; Williamson S; Ryu J; Gaspar LE; Edelman MJ; Dakhil SR; Sides SD; Crowley JJ; Gandara DR;
Clin Cancer Res; 2004 Aug; 10(16):5418-24. PubMed ID: 15328179
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
[TBL] [Abstract][Full Text] [Related]
9. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer.
Birch R; Weaver CH; Hainsworth JD; Bobo C; Greco FA
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-135-S12-137. PubMed ID: 9331138
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1996 Dec; 23(6 Suppl 16):7-10. PubMed ID: 9007113
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years.
Neubauer M; Schwartz J; Caracandas J; Conkling P; Ilegbodu D; Tuttle T; Asmar L
J Clin Oncol; 2004 May; 22(10):1872-7. PubMed ID: 15143079
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
Hainsworth JD; Stroup SL; Greco FA
Cancer; 1996 Jun; 77(12):2458-63. PubMed ID: 8640693
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS
Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
[TBL] [Abstract][Full Text] [Related]
15. Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group.
Jett JR; Hatfield AK; Hillman S; Bauman MD; Mailliard JA; Kugler JW; Morton RF; Marks RS; Levitt R
Cancer; 2003 May; 97(10):2498-503. PubMed ID: 12733149
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience.
Hainsworth JD; Burris HA; Greco FA
Semin Oncol; 2001 Apr; 28(2 Suppl 4):43-7. PubMed ID: 11479897
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
[TBL] [Abstract][Full Text] [Related]
18. [Pilot study of dose intensive weekly chemotherapy followed by cisplatin plus etoposide with concurrent thoracic irradiation for limited-disease small-cell lung cancer. West Japan Thoracic Oncology Group].
Isobe T; Fukuoka M; Negoro S; Sugiura T; Kawahara M; Kudoh S; Araki J; Nakagawa K; Yokozaki M; Yamakido M; Ariyoshi Y
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1091-6. PubMed ID: 10945001
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
Gridelli C; Curcio C; Iaffaioli RV; Brancaccio L; D'Aprile M; Gebbia V; Rossi A; Tortoriello A; Veltri E; Maione P; Barbarisi A; Gallo C; Guida C; Perrone F
Anticancer Res; 2001; 21(6A):4179-83. PubMed ID: 11911315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
